Skip to main content
. 2025 Jul 28;16(11):3473–3484. doi: 10.7150/jca.114975

Table 1.

Baseline characteristics of AGC patient treated with PD-1 inhibitors

Characteristics HSP90α (Before PSM) P value2 HSP90α (After PSM) P value2
≤82, N=511 >82, N=791 ≤82, N=411 >82, N=411
Gender 0.724 0.557
Male 38 (75%) 61 (77%) 33 (80%) 35 (85%)
Female 13 (25%) 18 (23%) 8 (20%) 6 (15%)
Age 0.986 0.594
≤65 33 (65%) 51 (65%) 31 (76%) 33 (80%)
>65 18 (35%) 28 (35%) 10 (24%) 8 (20%)
ECOG PS 0.679 >0.999
≤1 48 (94%) 76 (96%) 40 (98%) 39 (95%)
≥2 3 (6%) 3 (4%) 1 (2%) 2 (5%)
Peritoneum metastasis 0.483 0.607
Negative 39 (76%) 56 (71%) 30 (73%) 32 (78%)
Positive 12 (24%) 23 (29%) 11 (27%) 9 (22%)
Liver metastasis 0.679 0.507
Negative 29 (57%) 42 (53%) 23 (56%) 20 (49%)
Positive 22 (43%) 37 (47%) 18 (44%) 21 (51%)
Lung metastasis 0.275 >0.999
Negative 45 (88%) 64 (81%) 35 (85%) 35 (85%)
Positive 6 (12%) 15 (19%) 6 (15%) 6 (15%)
Lymph node metastasis 0.980 0.825
Negative 24 (47%) 37 (47%) 19 (46%) 20 (49%)
Positive 27 (53%) 42 (53%) 22 (54%) 21 (51%)
Metastasis sites 0.928 0.432
≤2 41 (80%) 63 (80%) 33 (80%) 30 (73%)
≥3 10 (20%) 16 (20%) 8 (20%) 11 (27%)
Treatment lines 0.064 0.775
≤2 34 (67%) 64 (81%) 33 (80%) 34 (83%)
≥3 17 (33%) 15 (19%) 8 (20%) 7 (17%)
Treatment types 0.783 0.416
Chemotherapy + targeted therapy 16 (31%) 21 (26%) 12 (29%) 10 (24%)
Chemotherapy 30 (59%) 48 (61%) 27 (66%) 25 (61%)
Others 5 (10%) 10 (13%) 2 (5%) 6 (15%)
HER-2 0.775 >0.999
Negative/Unknown 46 (90%) 70 (89%) 37 (90%) 36 (88%)
Positive 5 (10%) 9 (11%) 4 (10%) 5 (12%)
NLR 0.021 0.822
≤3 35 (69%) 38 (48%) 25 (61%) 24 (59%)
>3 16 (31%) 41 (52%) 16 (39%) 17 (41%)

1N(%)

2Pearson's chi-squared test; Fisher's exact test